Physician profile
Anne Tadeo
NPI 1083773717
$7,040.19
in general payments reported to CMS, 2019-2025
24 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $274 · 2021: $780 · 2022: $1,591 · 2023: $2,078 · 2024: $1,660 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,861.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,255.10 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $1,175.16 | 2019-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $702.63 | 2019-2025 | Rexulti, Brintellix |
| Abbvie INC. | $535.41 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $498.23 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $423.46 | 2019-2024 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $373.04 | 2022-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $370.18 | 2019-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $322.95 | 2019-2024 | Trintellix |
| Corium, LLC | $217.06 | 2023-2025 | Azstarys |
| Indivior INC. | $181.05 | 2023-2024 | Perseris |
| Idorsia Pharmaceuticals US INC | $160.71 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $155.33 | 2023-2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $148.13 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $86.85 | 2022-2024 | Fanapt, Hetlioz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $82.57 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $81.46 | 2024 | Qelbree |
| Sunovion Pharmaceuticals INC. | $68.71 | 2019-2022 | |
| Brainsway USA INC | $68.15 | 2021-2023 | |
| Allergan, INC. | $44.35 | 2019-2020 | |
| Noven Therapeutics, LLC | $44.30 | 2024 | Xelstrym, Secuado |
| Avion Pharmaceuticals | $16.64 | 2023 | Methylphenidate Hydrochloride |
| Biogen, INC. | $14.94 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.78 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Tadeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.